-
Tytuł:
-
The effects of statin monotherapy on depressive symptoms: A systematic review and meta-analysis.
-
Autorzy:
-
De Giorgi R; University of Oxford, Department of Psychiatry, Warneford Hospital, Warneford Lane, Oxford, Oxfordshire OX3 7JX, United Kingdom; Oxford Health NHS Foundation Trust, Warneford Hospital, Warneford Lane, Oxford, Oxfordshire OX3 7JX, United Kingdom. Electronic address: .
Waters S; University of Oxford, Department of Psychiatry, Warneford Hospital, Warneford Lane, Oxford, Oxfordshire OX3 7JX, United Kingdom.
Pesci NR; University of Turin, Department of Neurosciences 'Rita Levi Montalcini', Via Cherasco 15, Turin 10126, Italy.
Rosso G; University of Turin, Department of Neurosciences 'Rita Levi Montalcini', Via Cherasco 15, Turin 10126, Italy.
Cowen PJ; University of Oxford, Department of Psychiatry, Warneford Hospital, Warneford Lane, Oxford, Oxfordshire OX3 7JX, United Kingdom; Oxford Health NHS Foundation Trust, Warneford Hospital, Warneford Lane, Oxford, Oxfordshire OX3 7JX, United Kingdom.
Harmer CJ; University of Oxford, Department of Psychiatry, Warneford Hospital, Warneford Lane, Oxford, Oxfordshire OX3 7JX, United Kingdom.
-
Źródło:
-
Journal of affective disorders [J Affect Disord] 2022 Aug 15; Vol. 311, pp. 336-343. Date of Electronic Publication: 2022 May 24.
-
Typ publikacji:
-
Journal Article; Meta-Analysis; Review; Systematic Review; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Amsterdam, Elsevier/North-Holland Biomedical Press.
-
MeSH Terms:
-
Depression*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects
Antidepressive Agents/adverse effects ; Humans
-
Grant Information:
-
MR/S003037/1 United Kingdom MRC_ Medical Research Council; 102176/Z/13/Z United Kingdom WT_ Wellcome Trust; 216452/Z/19/Z United Kingdom WT_ Wellcome Trust
-
Contributed Indexing:
-
Keywords: Antidepressant; Depression; Depressive symptoms; Statin; meta-analysis
-
Substance Nomenclature:
-
0 (Antidepressive Agents)
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
-
Entry Date(s):
-
Date Created: 20220526 Date Completed: 20220620 Latest Revision: 20230322
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.jad.2022.05.113
-
PMID:
-
35618167
-
Introduction: Statins have been proposed as a strategy for treating depression, but their benefit in the absence of concurrent antidepressant treatment is unclear. This meta-analysis investigated the antidepressant effects of statin monotherapy in the general population.
Methods: We conducted a literature search of randomised controlled trials using any statin monotherapy versus any control condition for depressive symptoms. Our primary efficacy outcome was the mean value on any standardised scale for depression at study endpoint. We also measured efficacy at three further timepoints (<6 months, 6-12 months, >12 months), as well as acceptability, tolerability, and safety. Respectively, continuous and dichotomous outcomes were computed using standardised mean difference (SMD) or relative risk (RR) with 95% confidence intervals (CI) using a random-effect model.
Results: Pooled analyses did not show that statin monotherapy improves depressive symptoms at endpoint (N = 2712 SMD = -0.18; 95% CI = -0.41 to 0.04), nor at any other specific timepoint. No difference between statins and control was identified for any of the other outcome measures.
Discussion: These results differ from those of previous meta-analyses and, compounded by more recently available evidence, suggest that statins may not have intrinsic antidepressant properties, but may be useful for the management of depression in add-on to antidepressants.
Limitations: Data from heterogeneous populations and using different statins were pooled, though several sensitivity and subgroup analyses were performed to account for that. PROSPERO registration: CRD42022306653. https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=306653.
(Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
